Piper Sandler kept USD 165.00 target for Corcept Therapeutics stock

Published on 10/20/2026 at 22:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Piper Sandler kept a USD 165.00 target on October 7, 2026. Corcept Therapeutics stock costs EUR 103.85 on October 20, 2026.

Analyst target and earnings

Piper Sandler set a USD 165.00 target for Corcept Therapeutics on October 7, 2026.
Second-quarter revenue reached USD 256.15 million, up 31.70 percent year over year.
Corcept Therapeutics stock traded at EUR 103.85 at Lang & Schwarz on October 20, 2026 at 9:52 p.m. CEST.
Next earnings are estimated for November 4, 2026.

CORT, US2183521028, Illustration mit AI erstellt.

Corcept Therapeutics (US2183521028) had a USD 165.00 price target from Piper Sandler on October 7, 2026, when analyst David Amsellem reiterated a Buy rating, as Markets Insider reported. Corcept also generated USD 256.15 million in second-quarter revenue, up 31.70 percent from USD 194.43 million a year earlier, according to Markets Insider. At Lang & Schwarz on October 20, 2026 at 9:52 p.m. CEST, Corcept Therapeutics stock was trading at EUR 103.85.

Revenue growth sets the baseline

The second-quarter figure was accompanied by net profit of USD 42.14 million, compared with USD 35.15 million in the same quarter of 2025. The revenue comparison gives investors a clearer operating benchmark than the share price alone, because it connects the valuation to a reported period and an identifiable prior-year figure.

Nasdaq valuation remains demanding

On the Nasdaq, Corcept Therapeutics was last quoted at USD 116.45 on October 20, 2026 at 4:00 p.m. ET. The same market snapshot put the company at a USD 12.6 billion market capitalization, with a 52-week range of USD 28.66 to USD 126.38, while the price-to-earnings ratio was 277.31.

What comes next for the company?

MarketBeat lists November 4, 2026 as Corcept Therapeutics' estimated next earnings date. The appointment gives the next reporting event a concrete timetable, while the USD 165.00 target remains the clearest current analyst reference in the recent coverage.

Analyst target meets operating growth

The target sits against a business that expanded second-quarter revenue by USD 61.72 million year over year, from USD 194.43 million to USD 256.15 million. Piper Sandler's target is also materially above the latest Nasdaq quote, although the two prices are in different currencies and are not combined into a single percentage calculation.

Stock price and next date

Corcept Therapeutics combines a USD 165.00 Piper Sandler target dated October 7, 2026 with second-quarter revenue of USD 256.15 million and a USD 12.6 billion market capitalization. The next estimated earnings date is November 4, 2026. The further course of trading is shown by the continuously updated real-time quote of Corcept Therapeutics stock.